B Part Of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine program on carriage of Neisseria meningitidis

B Part Of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine program on carriage of Neisseria meningitidis

<br/><strong>Introduction: </strong>Invasive meningococcal disease is uncommon but associated with a high-case fatality rate. Carriage prevalence of the causative bacteria, Neisseria meningitidis, is high in adolescents. A large (n=34 500) cluster randomised controlled trial (RCT)...

Bibliográfalaš dieđut
Váldodahkkit:	Marshall, H, McMillan, M, Koehler, A, Lawrence, A, Maclennan, J, Maiden, M, Ramsay, M, Ladhani, S, Trotter, C, Borrow, R, Finn, A, Sullivan, T, Richmond, P, Kahler, C, Whelan, J, Vadivelu, K
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	BMJ Publishing Group 2019

Geahča maid

B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents
Dahkki: Marshall, HS, et al.
Almmustuhtton: (2018)

Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
Dahkki: Eva Hong, et al.
Almmustuhtton: (2021-12-01)

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
Dahkki: Susanna Esposito, et al.
Almmustuhtton: (2015-01-01)

Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland
Dahkki: Mulhall, R, et al.
Almmustuhtton: (2018)

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
Dahkki: Yara Ruiz García, et al.
Almmustuhtton: (2021-10-01)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
Dahkki: Véronique Abitbol, et al.
Almmustuhtton: (2023-08-01)

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
Dahkki: Margherita Bodini, et al.
Almmustuhtton: (2020-10-01)

Meningococcal B vaccine (4CMenB): the journey from research to real world experience
Dahkki: Rino Rappuoli, et al.
Almmustuhtton: (2018-12-01)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
Dahkki: Alessia Biolchi, et al.
Almmustuhtton: (2019-03-01)

Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
Dahkki: Emilio Pérez-Trallero, et al.
Almmustuhtton: (2014-01-01)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
Dahkki: Emilija Sereikaitė, et al.
Almmustuhtton: (2023-02-01)

Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB)
Dahkki: Ignacio Hernández-García, et al.
Almmustuhtton: (2020-10-01)

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B <italic toggle="yes">Neisseria meningitidis</italic> Isolated from 2009 to 2013 in the Republic of Ireland
Dahkki: Robert M. Mulhall, et al.
Almmustuhtton: (2018-08-01)

A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)
Dahkki: Gary S. Marshall, et al.
Almmustuhtton: (2023-12-01)

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
Dahkki: Isabelle Leduc, et al.
Almmustuhtton: (2020-12-01)

Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B <italic toggle="yes">Neisseria meningitidis</italic> Strains and Their Predicted Coverage by the 4CMenB Vaccine
Dahkki: Raymond S. W. Tsang, et al.
Almmustuhtton: (2020-04-01)

The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.
Dahkki: Rollier, C, et al.
Almmustuhtton: (2014)

4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion
Dahkki: Phung Nguyen The Nguyen, et al.
Almmustuhtton: (2024-03-01)

Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020
Dahkki: Alessandro Muzzi, et al.
Almmustuhtton: (2024-06-01)

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.
Dahkki: Maria João Simões, et al.
Almmustuhtton: (2017-01-01)

Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
Dahkki: María Fernández-Prada, et al.
Almmustuhtton: (2018-09-01)

Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010–2016
Dahkki: Rodrigues, C, et al.
Almmustuhtton: (2018)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
Dahkki: Maria Stella, et al.
Almmustuhtton: (2020-04-01)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
Dahkki: Snape, M, et al.
Almmustuhtton: (2015)

4CMenB journey to the 10-year anniversary and beyond
Dahkki: Véronique Abitbol, et al.
Almmustuhtton: (2024-12-01)

Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents
Dahkki: Lorenzo Argante, et al.
Almmustuhtton: (2024-12-01)

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016
Dahkki: Charlene M.C. Rodrigues, et al.
Almmustuhtton: (2018-04-01)

The genomic epidemiology of Neisseria meningitidis carriage from a randomised controlled trial of 4CMenB vaccination in an asymptomatic adolescent populationResearch in context
Dahkki: Lex E.X. Leong, et al.
Almmustuhtton: (2024-02-01)

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS
Dahkki: Sarah J. Tozer, et al.
Almmustuhtton: (2021-09-01)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
Dahkki: Kesanopoulos, K, et al.
Almmustuhtton: (2018)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
Dahkki: Cecilia Fazio, et al.
Almmustuhtton: (2021-07-01)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
Dahkki: Helen S. Marshall, et al.
Almmustuhtton: (2021-05-01)

Exploiting real-time genomic surveillance data to assess 4CMenB meningococcal vaccine performance in Scotland, 2015 to 2022
Dahkki: Rodrigues, CMC, et al.
Almmustuhtton: (2023)

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022
Dahkki: C. M. C. Rodrigues, et al.
Almmustuhtton: (2023-04-01)

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010–2014
Dahkki: Adriana Efron, et al.
Almmustuhtton: (2024-12-01)

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
Dahkki: Rivero-Calle I, et al.
Almmustuhtton: (2019-10-01)

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
Dahkki: Davis, K, et al.
Almmustuhtton: (2021)

An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol
Dahkki: Caroline Thng, et al.
Almmustuhtton: (2023-03-01)

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
Dahkki: Carr, J, et al.
Almmustuhtton: (2020)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
Dahkki: Erdem Gönüllü, et al.
Almmustuhtton: (2019-01-01)